there is a very good report on evamist in kv pharmaceuticals annual report issued last night.the company said that evamist is been marketed by 330 professional sales reps.it has continued to show increasing prescription trends on track with company expectations and comparing favourably to prior analogous product launches.total prescriptions are trending to more than 2000 per month based on recent weekly data.in addition the product is receiving positive feedback from physicians and patients alike.the company believes evamist will make a positive contribution to net revenue in 2009
ACR Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
